Adalimumab Products
Customize your policy alerts
Sign up for all Mass General Brigham Health Plan policy alerts
Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs prior authorization and pharmacy coverage for preferred adalimumab products under the Commercial/Exchange pharmacy benefit. It establishes diagnosis-specific initial authorization criteria, continuation requirements, quantity limits, approval durations, and specialty-pharmacy dispensing requirements for members with rheumatoid arthritis and other labeled inflammatory conditions.
Effective January 1, 2027, adalimumab-aaty, adalimumab-adaz, and Hadlima are the Plan's preferred adalimumab products, while all other adalimumab products are nonformulary.
The policy was renamed to Adalimumab Products.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.